FRESH –First-in-Class Aminopeptidase-A Inhibitor Firibastat Fails in Resistant Hypertension
Key Points Hypertension remains a major public health threat contributing significantly to…
PRECISION –Dual Endothelin Receptor Antagonist Aprocitentan Superior to Placebo in Resistant Hypertension
Key Points Despite the many drug classes available to treat hypertension, the…
RAPID – Self-Administered Etripamil Improves PSVT Conversion to Sinus Rhythm
Key Points -The RAPID study achieved its primary efficacy endpoint of terminating…
NOVA – No significant difference in rate of post-op AF with botulinum toxin vs placebo
Key Points: -In a Phase II, dose-ranging trial of epicardial fat pad…
FLASH: The FlowTriever system has an excellent safety profile in the treatment of pulmonary embolism
Key Points: Mortality for acute PE remains high. While percutaneous mechanical thrombectomy…
Reported muscle pain and weakness often not due to statin therapy: meta-analysis shows.
Key Points Statin therapy is in wide use globally to prevent cardiovascular…
Radial cath associated with fewer deaths and bleeding: RTC study
Key Points Transradial access has emerged as the preferred initial access method…
Sacubitril/Valsartan “wins” against ramipril in post-hoc analysis of PARADISE-MI
Key Points The PARADISE-MI trial randomized patients to receive sacubitril/valsartan or ramipril…
PANTHER analysis suggests P2Y12 inhibitors safer, more effective than Aspirin, for secondary prevention
Key Points Antiplatelet therapy is a cornerstone of secondary prevention in patients…
Full-dose anticoagulation prevents thrombotic events in COVID patients: COVID-PACT
Key Points Given the increased thrombotic risk in COVID patients, there has…
Abbreviated DAPT continues to prevail beyond one year: MASTER-DAPT subanalysis shows
Key Points: In this pre-specified MASTER DAPT sub-study, patients with high bleeding…
Coronary Artery Plaque Activity Predicts Recurrent Cardiac Events: results from the PRE-18FFR Trial
Key Points Understanding the future risk of myocardial infarction and death for…
When and How Much Should We lower LDL and Systolic Blood Pressure in Our Patients? Artificial Intelligence and Causal Effects May Provide Answers
Key Points: • Current risk estimating algorithms exclude causal effects and therefore…
It’s Time to Randomize: Smartphone-Based Screening for Atrial Fibrillation – The Siteless, Digital, Randomized eBRAVE-AF Trial
Key Points Wearable technologies based on photoplethysmographic measurements of irregular pulses can…
Artificial Intelligence can improve detection of severe aortic stenosis from echocardiograms: AI-ENHANCED AS shows.
Key Points Aortic stenosis, despite being life-threatening, is often underdiagnosed. It is…
Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Milvexian to Antiplatelet Therapy After Acute Stroke: the AXIOMATIC-SSP trial.
Key Points Selective XIa inhibitor Milvexian may innovate the field of oral…
Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Asundexian to Antiplatelet Therapy After Acute Non-Cardioembolic Stroke – PACIFIC-STROKE
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral…
An Answer at Last with INVICTUS: Patients with Rheumatic Heart Disease and Mitral Stenosis Should Remain on Warfarin, as Rivaroxaban Has a Higher Mortality Risk.
Key Points While DOACs have revolutionized the field of atrial fibrillation for…
Uncoupling Hemostasis from Thrombosis: Adding Oral FXIa Inhibitor Asundexian to DAPT After Acute Myocardial Infarction – PACIFIC-AMI.
Key Points Selective XIa inhibitor Asundexian may innovate the field of oral…
AI outperforms humans in LVEF assessments: EchoNet-RCT
Despite major advances in the implementation of artificial intelligence (AI) in Cardiology,…